Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
O75208

UPID:
COQ9_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
O75208; A8K3L2; Q7L5V7; Q7Z5T6; Q8NBL4; Q9NTJ2; Q9P056

BACKGROUND:
The Ubiquinone biosynthesis protein COQ9, located in mitochondria, plays a pivotal role in the synthesis of coenzyme Q, a key component in the electron transport chain. It specifically binds phospholipids, aiding in the production of this crucial molecule for energy generation.

THERAPEUTIC SIGNIFICANCE:
Given its association with primary Coenzyme Q10 deficiency, a condition presenting with neurological and muscular symptoms, the study of Ubiquinone biosynthesis protein COQ9 holds therapeutic promise. Enhancing our understanding of COQ9 could lead to novel treatments for this and related disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.